An antibody raised against the cytokine interleukin 12 subunit (IL12 p35) encoded by IL12A; a growth factor for active T and natural killer (NK) cells and induces interferon gamma INF-γ production.
Catalogue number crb2005604 Antibody Anti-IL12A antibody Antigen Peptide KLH conjugated synthetic peptide crb1200808e Protein ID P29459 Aliases Interleukin-12 subunit alpha, IL-12A, CLMF p35, IL-12 subunit p35, NK cell stimulatory factor chain 1, NKSF1 Host Species Rabbit Antibody Type Polyclonal Concentration 1mg/ml Target IL12A Storage Stabilisers The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. Storage The product should be stored at -20°C for short term storage and long term storage. Avoid repeated freeze/ thaw cycles. References
Goris et al., (2012). Progress in multiple sclerosis genetics. Curr. genomics, 13(8): 646. PMID: 23730204.
Hirschfield et al., (2009). Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. NEJM., 360(24): 2544. DOI: 10.1056/NEJMx090024.
Kappen et al., (2015). Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease. PloS one, 10(3): e0119085. https://doi.org/10.1371/journal.pone.0119085.
IL12 is a heterodimer connected by a disulphide bond, one is encoded by IL12A and another IL12B. IL12 acts upon T cells inducing their differentiation; the interleukin induces production of INF-γ in resting peripheral blood mononuclear cells (PBMC). Furthermore, IL12 acts as a growth factor for activated T and natural killer (NK) cells, while enhancing the lytic activity of NK/lymphokine-activated killer cells. IL12 promotes T cell migration to the central nervous system by upregulating adhesion molecules – P-selectin glycoprotein ligand (PSGL-1) and chemokine receptor (CCR5).
Mutations in IL12A have been associated with Behcet Syndrome and Primary Biliary Cholangitis. IL12 also appears to play a role in multiple sclerosis pathogenesis. However, studies have shown administering ranges of IL12 doses can have a differential effect on cancer and virus response possibly due to IL12 and CD8+ T cell signal transduction during cancer surveillance. Use of this antibody against IL12 subunit alpha could further the research into the protein’s role in the immune response and signalling cascade.